VYVGART shows clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes.

argenx SE announced new data on VYVGART (efgartigimod alfa-fcab) at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine meeting. The data showed clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in the ADAPT SERON study, with ~60% of patients achieving minimal symptom expression (MSE). Real-world data also demonstrated >70% of patients treated with VYVGART meaningfully reduced glucocorticoid use while maintaining clinical benefit.